Malaria

Agreement Signed To Develop New Treatment

Published in TB and Outbreaks Week, March 20th, 2001

GlaxoSmithKline and the World Health Organization (WHO) announced the signing of an agreement for the development of a new treatment for malaria.

The product, known as LAPDAP, combines two existing anti-malarial compounds (chlorproguanil and dapsone) and is a potential life-saving medicine, WHO said.

The agreement aims at developing the drug as an oral treatment for uncomplicated malaria, primarily for use in Sub-Saharan Africa. Clinical trials in the region have shown that LAPDAP is effective in treating uncomplicated malaria resistant to other standard therapies.

The drug will be made available at a preferential price for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-03-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry